By Application, Type 2 Diabetes Mellitus Lead, and Obesity Registers Fastest Growth Type 2 diabetes mellitus accounted for the largest share of the semaglutide market with about 70.40%, driven by the drugs demonstrated reduction in HbA1c, weight loss, and cardiovascular risk
A team approach is always beneficial, and ophthalmologists should discuss with primary care providers and endocrinologists the risks and benefits of prescribing semaglutide in patients with specific eye conditions
Tirzepatides dual action can cause more frequent gastrointestinal side effects (nausea and diarrhea)
The Ozempic ladder reaches 2.0 mg weekly, but doubling from 1.0 to 2.0 mg added only about 0.23 percentage points of HbA1c reduction and 0.9 kg of weight loss. Beyond 1.0 mg, most of the added effect is on weight rather than glucose
This leads to reduced hunger and calorie intake and slows down stomach emptying, promoting a feeling of fullness for longer periods